Physician

Amor Ruyintan Mehta, MD

According to 2025 Medicare claims, Amor Mehta, MD (NPI: 1558566471) practices epileptologists in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Monmouth, NJ. This provider's primary affiliated billing organization is AMOR MEHTA MD - NEUROLOGY CENTER FOR EPILEPSY AND SEIZURES, LLC (NPI: 1174006233; TIN: 831177547) and primary practice location at 07746-1085. Mehta is affiliated with the RWJBH Accountable Care, LLC (ACO ID: A1247), Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171), and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under both the MSSP and REACH models.

Mehta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 682 traditional Medicare patients, billed 2,020 HCPCS/CPT codes, and received $476,643 in Medicare payments. The top billing code was 95819 (Measurement of brain wave activity (eeg), awake and asleep). Part D data shows 817 prescription claims across 193 beneficiaries totaling $989,881 in drug costs, led by Sabril (Vigabatrin). Open Payments data shows 133 records totaling $12,655. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $645,920 to $476,643. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $569,539 and ending at $989,881. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	799	1,791	$645,920
2016	914	2,028	$753,547
2017	846	2,110	$979,676
2018	707	1,519	$441,244
2019	163	854	$206,072
2020	256	1,207	$260,700
2021	363	1,540	$377,666
2022	312	1,336	$366,372
2023	396	1,877	$513,701
2024	682	2,020	$476,643

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	140	1,561	$569,539
2016	198	2,269	$902,980
2017	266	3,073	$1,328,741
2018	287	3,561	$1,765,226
2019	186	1,479	$960,301
2020	156	1,368	$902,238
2021	210	1,637	$1,050,594
2022	169	881	$604,813
2023	153	816	$740,540
2024	193	817	$989,881

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
95819	Measurement of brain wave activity (eeg), awake and asleep	236	248	$251
95816	Measurement of brain wave activity (eeg), awake and drowsy	231	235	$247
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	142	142	$165
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	339	455	$130
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	277	309	$94

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Sabril	Vigabatrin	13	390	$619,279
Vigabatrin	Vigabatrin	11	330	$93,559
Aptiom	Eslicarbazepine Acetate	20	720	$55,164
Keppra Xr	Levetiracetam	13	390	$54,952
Lamotrigine Er	Lamotrigine	29	2,070	$22,342

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	133	$12,655	SK Life Science, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amor Ruyintan Mehta, MD?

Tedicare shows public-source Medicare data for Amor Ruyintan Mehta, MD (NPI 1558566471), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amor Ruyintan Mehta, MD have ACO affiliation data?

Amor Ruyintan Mehta, MD is shown with ACO affiliation data for RWJBH Accountable Care, LLC (MSSP, ACO ID A1247), Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171), and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Amor Ruyintan Mehta, MD?

Amor Ruyintan Mehta, MD is linked to AMOR MEHTA MD - NEUROLOGY CENTER FOR EPILEPSY AND SEIZURES, LLC (billing NPI 1174006233) in the available physician profile data.

Does Amor Ruyintan Mehta, MD have Open Payments data?

Amor Ruyintan Mehta, MD has 133 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.